Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines
作者:Hong Lin、Dennis S. Yamashita、Ren Xie、Jin Zeng、Wenyong Wang、Jack Leber、Igor G. Safonov、Sharad Verma、Mei Li、Louis LaFrance、Joseph Venslavsky、Dennis Takata、Juan I. Luengo、Jason A. Kahana、Shuyun Zhang、Kimberly A. Robell、Dana Levy、Rakesh Kumar、Anthony E. Choudhry、Michael Schaber、Zhihong Lai、Barry S. Brown、Brian T. Donovan、Elisabeth A. Minthorn、Kristin K. Brown、Dirk A. Heerding
DOI:10.1016/j.bmcl.2009.11.061
日期:2010.1
The synthesis and evaluation of tetrasubstituted aminopyridines, bearing novel azaindazole hinge binders, as potent AKT inhibitors are described. Compound 14c was identified as a potent AKT inhibitor that demonstrated reduced CYP450 inhibition and an improved developability profile compared to those of previously described trisubstituted pyridines. It also displayed dose-dependent inhibition of both phosphorylation of GSK3b and tumor growth in a BT474 tumor xenograft model in mice. (C) 2009 Elsevier Ltd. All rights reserved.
[EN] INHIBITORS OF AKT ACTIVITY<br/>[FR] INHIBITEURS DE L'ACTIVITÉ Akt
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2009032651A1
公开(公告)日:2009-03-12
Invented are novel substituted pyridine compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.